Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2008-05-27
2008-05-27
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C530S300000
Reexamination Certificate
active
11748992
ABSTRACT:
The present invention features antibodies and antibody fragments that specifically bind a CD4-inducible HIV gp120 epitope that is enhanced by binding a co-receptor for HIV, such as CCR5 or CXCR4, and pharmaceutical compositions comprising the antibodies or antibody fragments. The invention also features nucleic acids encoding the antibodies or antibody fragments, pharmaceutical compositions comprising the nucleic acids encoding the antibodies or antibody fragments, vectors comprising the nucleic acids, and cells comprising the vectors. The invention further features methods of identifying antibodies or antibody fragments with broadly neutralizing activity against HIV. The invention also features methods of inhibiting HIV entry into cells and methods of inhibiting replication of HIV in mammals, using the antibodies and nucleic acids of the invention.
REFERENCES:
patent: 5518723 (1996-05-01), DeVico et al.
patent: 5804440 (1998-09-01), Burton et al.
patent: 5925741 (1999-07-01), Gershoni
patent: 6030772 (2000-02-01), Devico et al.
patent: 6135941 (2000-10-01), Hillman et al.
patent: 6261558 (2001-07-01), Barbas et al.
patent: 6680209 (2004-01-01), Buechler et al.
patent: 7084257 (2006-08-01), Deshpande et al.
patent: 2003/0018004 (2003-01-01), Kingsman et al.
patent: 2003/0133939 (2003-07-01), Ledbetter et al.
patent: 2003/0147881 (2003-08-01), Cheung et al.
patent: 2004/0039172 (2004-02-01), Haynes et al.
patent: 1 054 018 (2000-11-01), None
patent: WO 91/00360 (1991-01-01), None
patent: WO 93/15747 (1993-08-01), None
patent: WO 94/07922 (1994-04-01), None
patent: WO 96/15273 (1996-05-01), None
patent: WO 99/24464 (1999-05-01), None
patent: WO 00/40616 (2000-07-01), None
patent: WO 00/55207 (2000-09-01), None
patent: WO 00/69914 (2000-11-01), None
patent: WO 02/093519 (2002-11-01), None
patent: WO 03/033666 (2003-04-01), None
patent: WO 03/092630 (2003-11-01), None
patent: WO 03/095492 (2003-11-01), None
Burton et al.,Science, 266, 1024-1027 (1994).
Conley et al.,Proc. Natl. Acad. Sci. USA, 91, 3348-3352 (1994).
Dimitrov,Cell, 101, 697-702 (2000).
Dimitrov,Nat. Med., 2 (6), 640-641 (1996).
Golding et al.,Aids Research and Human Retroviruses, 15(2), 149-159 (1999).
Hoogenboom et al.,Immunotechnology, 4, 1-20 (1998).
Kilby et al.,Nature Medicine, 4(11), 1302-1307 (1998).
Kwong et al.,Nature, 393, 648-659 (1998).
Lapham et al.,Science, 274, 602-605 (1996).
Mirzabekov et al.,J Biological Chemistry, 274(40), 28745-28750 (1999).
Mirzabekov et al.,Nature Biotechnology, 18, 649-654 (2000).
Moulard et al.,PNAS, 99(10), 6913-6918 (2002).
Sattentau et al.,J. of Virology, 67(12), 7383-7393 (1993).
Trkola et al.,J. Virol., 70 (2), 1100-1108 (1996).
Thali et al.,Journal of Virology, 67, 3978-3988 (1993).
Wyatt et al.,J. of Virology, 69(9), 5723-5733 (1995).
Xiao et al.,Proc. Natl. Acad. Sci., USA 96, 7496-7501 (Jun. 1999).
Ahlborg et al., “Immune responses in congenic mice to multiple antigen peptides based on defined epitopes from the malaria antigen Pf332,”Immunology, 88 (4), 630-635 (1996).
Barbas et al., “In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity,”Proc. Natl. Acad. Sci. USA, 91 (9), 3809-3813 (1994).
Binley et al., “Human Antibody Responses to HIV Type 1 glycoprotein 41 Cloned in Phage Display Libraries Suggest Three Major Epitopes Are Recognized and Give Evidence for Conserved Antibody Motifs in Antigen Binding,”AIDS Research and Human Retroviruses, 12 (10), 911-924 (1996).
Boots et al., “Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries,”AIDS Res. Hum. Retrovir., 13 (18), 1549-1559 (1997).
Brenneman et al., “VIP and d-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death,”Brain Res., 838, 27-36 (1999).
Broliden et al., “Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers,”Immunol. Lett., 79 (1-2), 29-36 (2001).
Burioni et al., “Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro,”Proc. Natl. Acad. Sci. USA, 91 (4), 355-359 (1994).
Celada et al., “Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding,”J. Exp. Med., 172 (4), 1143-1150 (1990).
Chan et al., “HIV entry and its inhibition,”Cell, 93 (5), 681-684 (1998).
Cheng et al., “Construction, Expression and Characterization of the Engineered Antibody Against Tumor Surface Antigen,”Cell Research, 13 (1), 35-48 (2003).
Choudhry et al., “Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies,”Virology, 363 (1), 79-90 (2007).
Chow et al., “Conserved Structures Exposed in HIV-1 Envelope Glycoproteins Stabilized by Flexible Linkers as Potent Entry Inhibitors and potential Immunogens,”Biochem., 41, 7176-7182 (2002).
Dalgleish et al., “The CD4 (T4) Antigen is an Essential Component of the Receptor for the AIDS Retrovirus,”Nature, 312 (5996), 763-767 (1984).
Deen et al., “A soluble form of CD4 (T4) protein inhibits AIDS virus infection,”Nature, 331 (6151), 82-84 (1988).
Devico et al., “Covalently crosslinked complexes of human immunodeficiency virus type 1 (HiV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates,”Virology, 218 (1), 258-263 (1996).
Dey et al., “Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor,”J. Virol., 77 (5), 2859-2865 (2003).
Dimitrov, “Virus Entry: Molecular Mechanisms and Biomedical Applications,”Nature Reviews Microbiology, 2, 109-122 (2004).
Finnegan et al., “Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion,”J. Virol., 76 (23), 12123-12134 (2002).
Fisher et al., “HIV infection is blocked in vitro by recombinant soluble CD4,”Nature, 331 (6151), 76-78 (1988).
Gershoni et al., “HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex,”FASEB J., 7 (12), 1185-1187 (1993).
Gorny et al., “The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope,”J. Virol., 78 (5), 2394-2404 (2004).
Goudsmit et al., “Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees,”Proc. Natl. Acad. Sci. USA, 85 (12), 4478-4482 (1988).
Javaherian et al., “Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein,”Proc. Natl. Acad. Sci. USA, 86 (17), 6768-6772 (1989).
Jellis et al., “Defining critical residues in the epitope for a HIV-neutralizing monoclonal antibody using phage display and peptide array technologies,”Gene, 137 (1), 63-68 (1993).
Kang et al., “Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120,”J. Virol., 68 (9), 5854-5862 (1994).
Klatzmann et al., “T-lymphocyte T4 Molecule Behaves as the Receptor for Human Retrovirus LAV,”Nature, 312 (5996), 767-768 (1984).
Labrijn et al. “Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Ster
Burton Dennis
Dimitrov Dimiter S.
Moulard Maxime
Phogat Sanjay K.
Shu Yuuei
Campell Bruce R.
Kinsey White Nicole
Leydit, Voit & Mayer, Ltd.
The Scripps Research Institute
The United States of America as represented by the Department of
LandOfFree
Broadly cross-reactive neutralizing antibodies against Human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Broadly cross-reactive neutralizing antibodies against Human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Broadly cross-reactive neutralizing antibodies against Human... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3942718